Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scene 2: Vernakalant in Atrial Flutter
NCT00476112Phase 3Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Aug 2003
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in atrial flutter (AFL) comparing Vernakalant with Placebo (2 arms). Primary endpoint: Conversion of Atrial Flutter to Sinus Rhythm. Started Aug 2003; status: completed.
02
Drugs
vernakalant
03
Conditions
atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00476112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476112.